Molecular medicine of gastric adenocarcinomas

Expert Reviews in Molecular Medicine

Volumn 7, Issue 17, 2005, Pages 1-13

  Keller, Gisela ^a   Höfler, Heinz ^a   Becker, Karl Friedrich ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CISPLATIN; DNA; FLUOROURACIL; GROWTH FACTOR; MONOCLONAL ANTIBODY; TUMOR SUPPRESSOR PROTEIN; TYROSINE KINASE RECEPTOR; UVOMORULIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL CYCLE REGULATION; DISEASE ASSOCIATION; DNA POLYMORPHISM; FAMILIAL CANCER; GASTRECTOMY; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR DYNAMICS; ONCOGENE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; STOMACH ADENOCARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; HUMANS; IMMUNOTHERAPY; STOMACH NEOPLASMS;

EID: 33645798905     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399405009592     Document Type: Review

References (92)

1. Lauren, P. (1965) The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand 64, 31-49, PubMed: 14320675
2. Fenoglio-Preiser, C. et al. (2000) Gastric carcinoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. (Hamilton, S.R. and Aaltonen, L.A., ads), pp. IARC Press, Lyon, France
3. Kelley, J.R. and Duggan, J.M. (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56, 1-9, PubMed: 12589864
4. Oberhuber, G. and Stolte, M. (2000) Gastric polyps: An update of their pathology and biological significance. Virchows Arch 437, 581-590, PubMed: 11193468
5. La Vecchia, C. et al. (1992) Trends of cancer mortality in Europe, 1955-1989: I, Digestive sites. Eur J Cancer 28, 132-235, PubMed: 1567665
6. Palli, D. et al. (1994) Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 3, 15-18, PubMed: 8118379
7. Guilford, P. et al. (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392, 402-405, PubMed: 9537325
8. El-Omar, E.M. et al. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-402, PubMed: 10746728
9. Machado, J.C. et al. (2003) A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 125, 364-371, PubMed: 12891537
10. Gayther, S.A. et al. (1998) Identification of germline E-cadherin mutations in gastric cancer families of European origin. Cancer Res 58, 4086-4089, PubMed: 9751616
11. Richards, F.M. et al. (1999) Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 8, 607-610, PubMed: 10072428
12. Keller, G. et al. (1999) Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 155, 337-342, PubMed: 10433926
13. Guilford, P.J. et al. (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 14, 249-255, PubMed: 10477433
14. Dussaulx-Garin, L. et al. (2001) A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extra-digestive dissemination. Eur J Gastroenterol Hepatol 13, 711-715, PubMed: 11434599
15. Jonsson, B.A. et al. (2002) Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer 98, 838-843, PubMed: 11948460
16. Oliveira, C. et al. (2002) Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 19, 510-517, PubMed: 11968083
17. Humar, B. et al. (2002) Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Hum Mutat 19, 518-525, PubMed: 11968084
18. Keller, G. et al. (2004) Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet 41, e89, PubMed: 15173255
19. Oliveira, C. et al. (2004) E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer 40, 1897-1903, PubMed: 15288293
20. Brooks-Wilson, A.R. et al. (2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: Assessment of 42 new families and review of genetic screening criteria. J Med Genet 41, 508-517, PubMed: 15235021
21. Oliveira, K. et al. (2004) Genetic screening for familial gastric cancer. Hereditary Cancer Clinic Practice 2, 51-64
22. Becker, K.F. et al. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54, 3845-3852, PubMed: 8033105
23. Berx, G. et al. (1998) Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 12, 226-237, PubMed: 9744472
24. Pharoah, P.D., Guilford, P. and Caldas, C. (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121, 1348-1353, PubMed: 11729114
25. Caldas, C. et al. (1999) Familial gastric cancer: Overview and guidelines for management. J Med Genet 36, 873-880, PubMed: 10593993
26. Watson, P. and Lynch, H.T. (2001) Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 1, 57-60, PubMed: 14574017
27. Lynch, H.T. and de la Chapelle, A. (2003) Hereditary colorectal cancer. N Engl J Med 348, 919-932, PubMed: 12621137
28. Aarnio, M. et al. (1997) Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 74, 551-555, PubMed: 9355980
29. Malkin, D. et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238, PubMed: 1978757
30. Kleihues, P. et al. (1997) Tumors associated with p53 germline mutations: A synopsis of 91 families. Am J Pathol 150, 1-13, PubMed: 9006316
31. Varley, J.M. et al. (1995) An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet 32, 942-945, PubMed: 8825920
32. Horio, Y. et al. (1994) Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. Oncogene 9, 1231-1235, PubMed: 8134126
33. Jarvinen, H., Nyberg, M. and Peltokallio, P. (1983) Upper gastrointestinal tract polyps in familial adenomatosis coli. Gut 24, 333-339, PubMed: 6832628
34. Hofgartner, W.T. et al. (1999) Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol 94, 2275-2281, PubMed: 10445562
35. Entius, M.M. et al. (1999) Molecular and phenotypic markers of hamartomatous polyposis syndromes in the gastrointestinal tract. Hepatogastroenterology 46, 661-666, PubMed: 10370593
36. Giardiello, F.M. et al. (1987) Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 316, 1511-1514, PubMed: 3587280
37. Howe, J.R., Mitros, F.A. and Summers, R.W. (1998) The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 5, 751-756, PubMed: 9869523
38. Woodford-Richens, K. et al. (2000) Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut 46, 656-660, PubMed: 10764709
39. Howe, J.R. et al. (1998) Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280, 1086-1088, PubMed: 9582123
40. Howe, J.R. et al. (2001) Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28, 184-187, PubMed: 11381269
41. Correa, P. and Shiao, Y.H. (1994) Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 54, 1941s-1943s, PubMed: 8137316
42. Jinawath, N. et al. (2004) Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene 23, 6830-6844, PubMed: 15273739
43. Tahara, E. (1995) Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer 75, 1410-1417, PubMed: 7889467
44. Kim, B. et al. (2003) Expression profiling and subtype-specific expression of stomach cancer. Cancer Res 63, 8248-8255, PubMed: 14678982
45. Boussioutas, A. et al. (2003) Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 63, 2569-2577, PubMed: 12750281
46. Keller, G. et al. (1995) Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract. Relation to clinicopathological data and family history. Am J Pathol 147, 593-600, PubMed: 7677173
47. dos Santos, N.R. et al. (1996) Microsatellite instability at multiple loci in gastric carcinoma: Clinicopathologic implications and prognosis. Gastroenterology 110, 38-44, PubMed: 8536886
48. Buonsanti, G. et al. (1997) Microsatellite instability in intestinal- and diffuse-type gastric carcinoma. J Pathol 182, 167-173, PubMed: 9274526
49. Lee, J.H. et al. (2004) Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 23, 4646-4654, PubMed: 15064707
50. Nakatsuru, S. et al. (1992) Somatic mutation of the APC gene in gastric cancer: Frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. Hum Mol Genet 1, 559-563, PubMed: 1338691
51. Nakatsuru, S. et al. (1993) Somatic mutations of the APC gene in precancerous lesion of the stomach. Hum Mol Genet 2, 1463-1465, PubMed: 8242071
52. Fodde, R. (2003) The multiple functions of tumour suppressors: It's all in APC. Nat Cell Biol 5, 190-192, PubMed: 12646874
53. Lustig, B. and Behrens, J. (2003) The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129, 199-221, PubMed: 12707770
54. Clements, W.M. et al. (2002) beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 62, 3503-3506, PubMed: 12067995
55. Ebert, M.P. et al. (2002) Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 23, 87-91, PubMed: 11756228
56. Ebert, M.P. et al. (2003) Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 21, 1708-1714, PubMed: 12721245
57. Takeichi, M. (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251, 1451-1455, PubMed: 2006419
58. Kemler, R. (1993) From cadherins to catenins: Cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9, 317-321, PubMed: 8236461
59. Graziano, F. et al. (2004) Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 10, 2784-2789, PubMed: 15102685
60. Tamura, G. et al. (2000) E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 92, 569-573, PubMed: 10749913
61. Batlle, E. et al. (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2, 84-89, PubMed: 10655587
62. Cano, A. et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76-83, PubMed: 10655586
63. Comijn, J. et al. (2001) The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7, 1267-1278, PubMed: 11430829
64. Thiery, J.P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454, PubMed: 12189386
65. Rosivatz, E. et al. (2002) Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 161, 1881-1891, PubMed: 12414534
66. Kuniyasu, H. et al. (1992) Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189, 227-232, PubMed: 1333188
67. Wang, Y.L. et al. (2002) Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma - emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepatogastroenterology 49, 1172-1176, PubMed: 12143229
68. Gamboa-Dominguez, A. et al. (2004) Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: A multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 17, 579-587, PubMed: 15073595
69. Mein, R.F., Vollmers, H.P. and Müller-Hermelink, H.K. (1994) Different expression of bcl-2 in diffuse and intestinal type stomach carcinomas. Oncol Rep 69, 943-946
70. Ayhan, A. et al. (1994) Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas. Jpn J Cancer Res 85, 584-591, PubMed: 8063611
71. Vollmers, H.P. et al. (1998) Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: First clinical and histopathological results. Oncol Rep 5, 549-552, PubMed: 9538151
72. Yasui, W. et al. (2000) Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 35 Suppl 12, 111-115, PubMed: 10779229
73. Takano, Y. et al. (2000) Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 156, 585-594, PubMed: 10666388
74. Muller, W. et al. (1999) Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer. J Pathol 189, 186-193, PubMed: 10547573
75. Lordick, F. et al. (2004) Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91, 540-551, PubMed: 15122603
76. Parker, W.B. and Cheng, Y.C. (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48, 381-395, PubMed: 1707544
77. Yeh, K.H. et al. (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82, 1626-1631, PubMed: 9576280
78. Metzger, R. et al. (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16, 309-316, PubMed: 9440758
79. Napieralski, R. et al. (2005) Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 11, 3025-3031, PubMed: 15837757
80. Terashima, M. et al. (2002) Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 22, 761-768, PubMed: 12014648
81. Giatromanolaki, A. et al. (2001) Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy. Am J Clin Oncol 24, 222-226, PubMed: 11404489
82. Kikuyama, S. et al. (2001) p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 21, 2149-2153, PubMed: 11501839
83. Ott, K. et al. (2003) Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9, 2307-2315, PubMed: 12796400
84. Huntsman, D.G. et al. (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344, 1904-1909, PubMed: 11419427
85. Lewis, F.R. et al. (2001) Prophylactic total gastrectomy for familial gastric cancer. Surgery 130, 612-617; discussion 617-619, PubMed: 11602891
86. Charlton, A. et al. (2004) Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53, 814-820, PubMed: 15138207
87. Schuhmacher, C. et al. (1999) Rapid detection of mutated E-cadherin in peritoneal lavage specimens from patients with diffuse-type gastric carcinoma. Diagn Mol Pathol 8, 66-70, PubMed: 10475380
88. Hayashi, N. et al. (1995) Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345, 1257-1259, PubMed: 7746054
89. Sloane, J.P. (1995) Molecules and micrometastases. Lancet 345, 1255-1256, PubMed: 7746053
90. Becker, K.F. et al. (1999) Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody. Am J Pathol 155, 1803-1809, PubMed: 10595908
91. Senekowitsch-Schmidtke, R. et al. (2001) Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 61, 2804-2808, PubMed: 11306447
92. Nakatani, H. et al. (1986) Detection of amplified DNA sequences in gastric cancers by a DNA renaturation method in gel. Jpn J Cancer Res 77, 849-853, PubMed: 3095279